Company profile for Bicara Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of immunotherapy. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.Just as we bring together two modalities in our ...
Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of immunotherapy. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.Just as we bring together two modalities in our bifunctional therapies, our work also bridges two continents with a team in Cambridge, Mass. and a dedicated research arm, supported by Biocon, in Bangalore, India.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Cambridge, Massachusetts 02142
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/01/3196851/0/en/Bicara-Therapeutics-Announces-Publication-of-an-Abstract-with-Preliminary-Phase-1b-Expansion-Cohort-Data-Evaluating-750mg-of-Ficerafusp-Alfa-Weekly-Plus-Pembrolizumab-in-1L-HPV-neg.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/10/3184421/0/en/Bicara-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/10/13/3165460/0/en/Bicara-Therapeutics-Announces-Ficerafusp-Alfa-Granted-Breakthrough-Therapy-Designation-by-U-S-FDA-for-1L-HPV-Negative-R-M-HNSCC.html

GLOBENEWSWIRE
13 Oct 2025

https://www.globenewswire.com/news-release/2025/08/27/3140348/0/en/Bicara-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
27 Aug 2025

https://www.globenewswire.com/news-release/2025/08/12/3131596/0/en/Bicara-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
12 Aug 2025

https://www.globenewswire.com/news-release/2025/06/03/3093174/0/en/Bicara-Therapeutics-to-Present-at-the-Goldman-Sachs-46th-Annual-Global-Healthcare-Conference.html

GLOBENEWSWIRE
03 Jun 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty